Valuation: Arsanis Inc

Market Cap 412M 353M 331M 303M 571M 39.32B 577M 3.91B 1.52B 19.84B 1.55B 1.51B 65.7B P/E 2026 *
-6.23x
P/E 2027 * -5.83x
Enterprise Value 322M 276M 258M 236M 445M 30.66B 450M 3.05B 1.19B 15.47B 1.21B 1.18B 51.23B EV / Sales 2026 *
20.1x
EV / Sales 2027 * 18.9x
Free-Float
91.56%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 -
Director of Finance/CFO 71 12/08/2025
President - 12/08/2025
Director TitleAgeSince
Chairman 71 01/07/2018
Director/Board Member 63 01/10/2018
Director/Board Member 65 29/03/2019
Change 5-day change 1-year change 3-year change Capi.($)
+27.91%-3.04% - - 412M
-1.06%+0.65%+77.42%+122.82% 1,100B
+0.53%+0.75%+53.10%+64.29% 658B
+0.48%+2.65%+28.06%+81.19% 470B
+0.92%+3.57%+43.82%+44.21% 372B
+1.25%+2.21%+26.77%+43.05% 304B
+3.02%+5.68%+4.24%+17.04% 264B
-0.36%+3.99%+53.31%+72.49% 239B
+2.86%+3.86%-16.20%-51.83% 213B
+1.38%+3.72%+30.33%+93.56% 184B
Average +3.69%+2.95%+33.43%+54.09% 422.54B
Weighted average by Cap. +0.45%+2.21%+45.68%+71.81%

Financials

2026 *2027 *
Net sales 15.98M 13.69M 12.83M 11.72M 22.12M 1.52B 22.34M 151M 58.92M 769M 60M 58.69M 2.55B 11.56M 9.91M 9.28M 8.48M 16M 1.1B 16.16M 109M 42.62M 556M 43.41M 42.46M 1.84B
Net income -86.82M -74.4M -69.71M -63.68M -120M -8.28B -121M -822M -320M -4.18B -326M -319M -13.83B -103M -88.18M -82.62M -75.47M -142M -9.81B -144M -975M -379M -4.95B -386M -378M -16.39B
Net Debt -90.8M -77.81M -72.91M -66.6M -126M -8.66B -127M -860M -335M -4.37B -341M -334M -14.46B -194M -166M -156M -142M -269M -18.49B -271M -1.84B -715M -9.33B -728M -713M -30.9B
Logo Arsanis Inc
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-